Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Molgramostim When Administered by Inhalation to Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Molgramostim (Primary)
- Indications Bronchitis; Cystic fibrosis; Pulmonary alveolar proteinosis; Respiratory distress syndrome
- Focus Adverse reactions
- Sponsors Serendex Pharmaceuticals
- 23 Nov 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 18 Jun 2015 New trial record